In prostate cancer, serum HGF has been identified as an independent prognostic factor for advanced disease [4,5] and c-Met expression in metastatic lesions frequently exceeds that of primary tumors, with positive expression reported in more than 90% of prostate cancer bone metastases [6,7]. This evidence concerns the gene HGF and prostate cancer.